Category: Include on Menu
-
Beam Therapeutics edges higher after new sickle cell therapy results
Beam Therapeutics Inc. (NASDAQ:BEAM) saw its shares rise 1.7% in premarket trading Monday after releasing updated results from its BEACON Phase 1/2 study evaluating ristoglogene autogetemcel (risto-cel) for sickle cell disease (SCD). The latest data, presented at the 67th American Society of Hematology Annual Meeting, showed mean fetal hemoglobin (HbF) induction above 60% along with…
-
Alx Oncology rallies on strong Phase 2 data for lymphoma therapy
Shares of Alx Oncology Holdings (NASDAQ:ALXO) jumped 12% in premarket trading Monday after the biotech reported encouraging Phase 2 results for its investigational therapy evorpacept. In the study, evorpacept was paired with the standard rituximab and lenalidomide (R2) regimen in previously untreated patients with indolent non-Hodgkin lymphoma (iNHL). The combination delivered complete responses in 92%…
-
Arcellx shares jump on strong multiple myeloma trial results
Arcellx Inc. (NASDAQ:ACLX) rallied 13.6% in premarket trading Monday after releasing encouraging data from its pivotal Phase 2 iMMagine-1 trial evaluating anitocabtagene autoleucel (anito-cel) in patients with relapsed or refractory multiple myeloma. In the latest update, the company reported a 96% overall response rate and a 74% complete response/stringent complete response rate at a median…
-
Dyne Therapeutics climbs after reporting strong DMD clinical data
Shares of Dyne Therapeutics (NASDAQ:DYN) gained 7% after the biotech unveiled encouraging topline findings from its Phase 1/2 DELIVER study evaluating Z-Rostudirsen in Duchenne Muscular Dystrophy (DMD). According to the update, the trial’s Registrational Expansion Cohort achieved its main goal, delivering a statistically meaningful rise in dystrophin to 5.46% at six months versus baseline. Dyne…
-
Dow Jones, S&P, Nasdaq, Wall Street, U.S. Futures Edge Higher As Wall Street Awaits Key Fed Decision
U.S. stock index futures signaled a slightly firmer start on Monday, suggesting equities may build on the modest advance seen at the end of last week. Early upside momentum is being supported by renewed optimism around the interest-rate outlook as investors brace for the Federal Reserve’s policy announcement later this week. The Fed is broadly…
-
Meta to introduce EU users a new option with reduced personalized ads to meet DMA rules
Meta (NASDAQ:META) will roll out a new choice for Facebook and Instagram users in the European Union, allowing them to access versions of the platforms that feature less personalized advertising, the European Commission announced. Under the plan, EU users will be presented with a clear choice: they may either consent to sharing their full data…
-
NextEra Energy shares rise after expanding partnership with Google Cloud on large-scale data center buildout
NextEra Energy (NYSE:NEE) climbed 2.85% on Monday after unveiling a major expansion of its collaboration with Google Cloud aimed at developing multiple gigawatt-scale data center campuses across the United States. Under the expanded partnership, the two companies will jointly build data centers along with the generation and capacity infrastructure needed to support them. Google Cloud…
-
Recursion Pharmaceuticals rises 7% after reporting strong mid-stage data in FAP study
Recursion Pharmaceuticals (NASDAQ:RXRX) gained 7% on Monday after releasing encouraging Phase 2 results for REC-4881, its investigational therapy for familial adenomatous polyposis (FAP)—a hereditary condition that currently has no approved treatments. According to the company, REC-4881 showed rapid and meaningful clinical activity. Three-quarters of evaluable patients experienced a decrease in total polyp burden, with a…
-
Wave Life Sciences jumps 40% on encouraging early results for obesity therapy WVE-007
Wave Life Sciences Ltd. (NASDAQ:WVE) soared 40% on Monday after releasing interim findings from its Phase 1 INLIGHT study evaluating WVE-007, an investigational therapy targeting obesity. A single 240 mg dose of WVE-007 produced notable improvements in body composition over a three-month period. Participants experienced a 9.4% reduction in visceral fat, a 4.5% decrease in…
-
Marvell shares decline on fears of losing cloud chip business to Broadcom and Alchip
Marvell Technology (NASDAQ:MRVL) slid 6% on Monday amid growing concerns that the semiconductor firm may be losing key hyperscaler design wins. The drop followed a report indicating Microsoft (NASDAQ:MSFT) is exploring future custom chip development with Broadcom (NASDAQ:AVGO), as well as a downgrade from Benchmark over worries about Amazon (NASDAQ:AMZN) shifting away from Marvell. According…